Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway
暂无分享,去创建一个
P. Dong | H. Watari | Guannan Zhao | J. Yue | G. Tigyi | Hui-jun Guo | Yaohong Wang | Jiaxing Wang | Baojin Wang | Wenjing Zhang | Bing Zhu | Wei Li | Junming Yue
[1] P. Dong,et al. FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways , 2022, Frontiers in Oncology.
[2] Runzhi Li,et al. Astaxanthin from Haematococcus pluvialis ameliorates the chemotherapeutic drug (doxorubicin) induced liver injury through the Keap1/Nrf2/HO-1 pathway in mice. , 2020, Food & function.
[3] Prakash Kulkarni,et al. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials , 2020, Expert opinion on investigational drugs.
[4] U. Menon,et al. Ovarian cancer screening: Current status and future directions. , 2020, Best practice & research. Clinical obstetrics & gynaecology.
[5] Sina Salari,et al. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4. , 2019, European journal of pharmacology.
[6] Sheng Hu,et al. The double inhibition of PDK1 and STAT3-Y705 prevents liver metastasis in colorectal cancer , 2019, Scientific Reports.
[7] R. Sears,et al. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer , 2019, BioDrugs.
[8] J. Tolson,et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours , 2019, British Journal of Cancer.
[9] M. Momeny,et al. Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status. , 2019, The international journal of biochemistry & cell biology.
[10] Sarah H. Johnson,et al. Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low‐Risk From Intermediate‐ and High‐Risk Prostate Cancer , 2019, Mayo Clinic proceedings.
[11] Philipp M Cromm,et al. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation. , 2018, Journal of the American Chemical Society.
[12] Charles Y. Lin,et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 , 2018, eLife.
[13] J. Tolson,et al. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 , 2018, Neuro-oncology.
[14] Jian Wang,et al. Sulforaphane regulates apoptosis- and proliferation-related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer , 2018, International journal of molecular medicine.
[15] V. Thiéry,et al. Sensitization of tumor cells to chemotherapy by natural products: A systematic review of preclinical data and molecular mechanisms. , 2018, Fitoterapia.
[16] Fei Liu,et al. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells , 2018, Cancer medicine.
[17] W. Cong,et al. A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma , 2018, Current Medical Science.
[18] Hui Zhou,et al. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation , 2018, Science China Life Sciences.
[19] N. Akhtar,et al. Plant derived anticancer agents: A green approach towards skin cancers. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[20] Ž. Bugarčić,et al. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives. , 2017, European journal of medicinal chemistry.
[21] P. Dong,et al. Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells , 2017, Oncotarget.
[22] V. Margulis,et al. Integrin signaling potentiates transforming growth factor‐beta 1 (TGF‐&bgr;1) dependent down‐regulation of E‐Cadherin expression – Important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma , 2017, Experimental cell research.
[23] W. Zhai,et al. Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma , 2017, Oncotarget.
[24] Zheng Wang,et al. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells , 2017, Drug design, development and therapy.
[25] Weiling Li,et al. Anti-tumor and chemosensitization effects of Cryptotanshinone extracted from Salvia miltiorrhiza Bge. on ovarian cancer cells in vitro. , 2017, Journal of ethnopharmacology.
[26] Hening Lin,et al. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.
[27] Shu Zhang,et al. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. , 2016, Biochemical and biophysical research communications.
[28] S. Dilruba,et al. Platinum-based drugs: past, present and future , 2016, Cancer Chemotherapy and Pharmacology.
[29] Bo Yang,et al. Cryptotanshinone suppresses the proliferation and induces the apoptosis of pancreatic cancer cells via the STAT3 signaling pathway. , 2015, Molecular medicine reports.
[30] E. Prochownik,et al. Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. , 2015, Journal of medicinal chemistry.
[31] A. R. Fernandes,et al. Organometallic compounds in cancer therapy: past lessons and future directions. , 2014, Anti-cancer agents in medicinal chemistry.
[32] Xiaoli Ma,et al. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells , 2014, Journal of Translational Medicine.
[33] D. Schlaepfer,et al. FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.
[34] J. Yue,et al. A miR-21 hairpin structure-based gene knockdown vector. , 2010, Biochemical and biophysical research communications.
[35] I. Bahar,et al. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. , 2009, Journal of medicinal chemistry.
[36] V. Golubovskaya,et al. N-MYC Regulates Focal Adhesion Kinase Expression in Human Neuroblastoma* , 2007, Journal of Biological Chemistry.
[37] Justis P. Ehlers,et al. DDEF1 Is Located in an Amplified Region of Chromosome 8q and Is Overexpressed in Uveal Melanoma , 2005, Clinical Cancer Research.
[38] G. McLean,et al. Focal adhesion kinase as a potential target in oncology , 2003, Expert opinion on pharmacotherapy.
[39] Stephen K. Burley,et al. X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.
[40] F. Halaweish,et al. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B , 2015, Tumor Biology.